Dr. Syed E. Abidi – Chairman
Dr. Syed E. Abidi – Chairman
Dr. Abidi is President and CEO of Pharmaceutics International, Inc. (Pii). Pii focuses on the development of formulations and delivery systems for solid, liquid and semi-solid dosage form pharmaceutical products for generic companies and client provided New Chemical Entity (NCE) compounds. During his career with Pii and other companies such as American Drug Development, Inc., Hercon Laboratories, and Schering Plough, Dr. Abidi has had extensive experience in complex dosage form development including solid oral, suspensions, liquids, topicals, small volume parenteral products, inhalation aerosols and transdermal products. Dr. Abidi has been an Assistant Professor at the School of Pharmacy of Duquesne University, a Research Associate at the School of Pharmacy at West Virginia University, and a Research Assistant at the School of Pharmacy at the University of Mississippi. Dr. Abidi earned his B.S. in Pharmacy from Karachi University, Pakistan and his M.S. and Ph.D. in Pharmaceutics from the University of Mississippi.

Mr. Kamlesh Haribhakti – EVP & CSO, Director
Mr. Haribhakti has extensive experience in all aspects of pharmaceutical development including formulations, analytical, pharmacokinetics, and regulatory. Mr. Haribhakti has been responsible for successfully developing, filing, and obtaining FDA approval for over 100 generic pharmaceutical products. Previously, Mr. Haribhakti was Managing Director of Dinesh Remedies Limited (DRL). Prior to DRL, Mr. Haribhakti was a Co-Founder and Chief Executive Officer of KVD Pharma until its sale to Amneal Pharmaceuticals in Dec. 2007. He has also served in R&D roles for several pharmaceutical companies throughout his career including Able Laboratories, Inc., McNeil Pharmaceuticals (a Johnson & Johnson company), Eon Laboratories, Inc. (now Sandoz, a Novartis Company), Faulding/Purepac Pharmaceutical Company (now Actavis, Inc.), and Ivax Pharmaceuticals, Inc. (now Teva Pharmaceuticals Industries Limited).

Mr. Hemanshu N. Pandya – President & CEO, Director
Mr. Pandya is an experienced pharmaceutical executive with a broad spectrum of commercial, operational, strategic and corporate development experience. Previously, Mr. Pandya was President and Chief Executive Officer of IGI Laboratories Inc. (NYSE AMEX: IG) a provider of topical formulation development, analytical, manufacturing and packaging services to the pharmaceutical industry. Prior to IGI, Mr. Pandya was Chief Operating Officer of NexMed Inc. (now Apricus Biosciences Inc – NASDAQ: APRI), responsible for R&D, Operations, and Corporate Development. He has also served in various senior management roles within the pharmaceutical industry including Senior Vice President of Business Development and Strategic Alliances for Andrx Pharmaceuticals (now Watson Pharmaceuticals – NYSE : WPI), Chief Commercial Officer for Putney, Inc., and senior management roles with Able Laboratories, Inc., Ivax Pharmaceuticals, Inc. (now Teva Pharmaceuticals Industries Limited – NYSE : TEVA) and Faulding/Purepac Pharmaceutical Company (now Actavis, Inc.)

Mr. Jay Wadekar – EVP, Director
Mr. Wadekar has more than twenty-five years of experience in areas of finance, corporate strategy, sales and senior leadership in the healthcare field. Mr. Wadekar has held numerous executive level positions throughout his career in biotechnology and pharmaceutical industries including Chairman and CEO of Able Laboratories, Inc. Most recently he served as a strategic advisor to Camber Pharmaceuticals, Inc. since its founding and was instrumental in building the executive team and setting up their Sales Operations systems.

Mr. Jason Wild – Director
Jason Wild is the President and Chief Investment Officer of JW Asset Management, LLC, the advisor for three investment partnerships. Mr. Wild received his license as a pharmacist in 1997, and subsequently founded JW Asset Management, LLC in 1998. The firm has a strong history of finding opportunities within the specialty pharmaceutical sector. Mr. Wild currently serves as Chairman of the Board at Arbor Pharmaceuticals, Inc. He is a graduate of the Arnold and Marie Schwartz College of Pharmacy where he received a bachelor’s degree in Pharmacy.

Mr. Ed Schutter – Director
Mr. Schutter is a seasoned executive with over 30 years of experience in the pharmaceutical industry. Mr. Schutter is currently President and Chief Executive Officer of Arbor Pharmaceuticals, a specialty pharmaceutical company focused on the cardiovascular, hospital, and pediatric markets as well as generics through its Wilshire division. He also serves on the board of directors at Arbor. Prior to joining Arbor, Mr. Schutter served as President and Chief Operating Officer of Sciele (Shionogi) Pharmaceuticals. Prior to Sciele, he served as VP of Global Business Development at Solvay Pharmaceuticals based in Basel, Switzerland. Mr. Schutter also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, Ga. Mr. Schutter has a BS in Pharmacy from Mercer University and an MBA from Kennesaw State University.

Mr. Michael Altman, CFA – Director
Mr. Altman is a Senior Analyst at Perceptive Advisors. He joined Perceptive in 2007 from First New York Securities where he was a healthcare analyst. He is focused on medical devices, diagnostics and healthcare services. Mr. Altman graduated from the University of Vermont with a B.S. in Finance.